FDA grants priority review to Boehringer’s blood clotting agent

Your Health Matters

(Reuters) – Boehringer Ingelheim Pharmaceuticals Inc said its emergency blood clotting agent was granted a priority review status by the U.S. Food and Drug Administration, accelerating the regulatory process by four months. The drug, idarucizumab is specifically being tested to reverse the blood thinning effects of Pradaxa, the privately held company said in a statement on Thursday. (Reporting by Amrutha Penumudi in Bengaluru; Editing by Savio D’Souza)
Go to Source

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave